Listeria monocytogenes bacteremia developed during treatment of COVID‐19

Jin Yamamoto; Keitaro Nakamoto; Teppei Shimasaki; Daisuke Kurai; Takeshi Saraya; Haruyuki Ishii

doi:10.1002/ccr3.8115

Clinical Case Reports (Nov 2023)

Listeria monocytogenes bacteremia developed during treatment of COVID‐19

Jin Yamamoto,
Keitaro Nakamoto,
Teppei Shimasaki,
Daisuke Kurai,
Takeshi Saraya,
Haruyuki Ishii

Affiliations

Jin Yamamoto: Department of Nephrology and Rheumatology Kyorin University School of Medicine Mitaka Tokyo Japan
Keitaro Nakamoto: Department of Respiratory Medicine Kyorin University School of Medicine Mitaka Tokyo Japan
Teppei Shimasaki: Department of General Medicine Kyorin University School of Medicine Mitaka Tokyo Japan
Daisuke Kurai: Department of General Medicine Kyorin University School of Medicine Mitaka Tokyo Japan
Takeshi Saraya: Department of Respiratory Medicine Kyorin University School of Medicine Mitaka Tokyo Japan
Haruyuki Ishii: Department of Respiratory Medicine Kyorin University School of Medicine Mitaka Tokyo Japan

DOI: https://doi.org/10.1002/ccr3.8115
Journal volume & issue: Vol. 11, no. 11
pp. n/a – n/a

Abstract

Read online

Key Clinical Message Listeria monocytogenes is an important pathogen in older patients and immunosuppressed patients, often causing bacteremia. Complications resulting from infections other than COVID‐19 must also be considered during COVID‐19 treatment.

Published in Clinical Case Reports

ISSN: 2050-0904 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Medicine (General)
Website: https://onlinelibrary.wiley.com/journal/20500904

About the journal

Abstract

Keywords